With thanks to the best sleuth on HC - here is an interesting article that I would love to hear some comments on - so why did the FDA push back this review date?
What additional data have the FDA got at their disposal?
Interesting - the plot thickens
https://www.fiercepharma.com/marketing/incyte-latest-to-fall-victim-to-jak-scrutiny-as-fda-pushes-back-jakafi-review-gvhd
Cell Therapy News/Articles, page-9522
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
0.073(7.47%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $3.336M | 3.256M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 36676 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 34251 | 26 |
View Market Depth
| Last trade - 13.23pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |